INTRODUCTION {#sec1-1}
============

Early post-operative pain is thought to be a common complaint after laparoscopic cholecystectomy, and persistent acute post-operative pain may result in a prolonged stay.\[[@ref1][@ref2]\] The use of opioids is the mainstay of treatment for post-surgical pain, and non-opioid medications can serve as a part of multimodal analgesia which is able not only to alleviate the pain following surgical procedures but also to reduce the side effects concurrent with standard opioid therapy. Gabapentinoids such as gabapentin and pregabalin have demonstrated some potential in reducing acute post-surgical pain as a part of multimodal analgesia due to their possible opioid-sparing effects and prevention of chronic post-surgical pain.\[[@ref3]\] For instance, the combination of gabapentinoids and cyclooxygenase two inhibitors are reported to be effective for post-operative analgesia.\[[@ref4][@ref5][@ref6]\]

Pregabalin is known as a structural analogue of the inhibitory neurotransmitter γ-aminobutyric acid.\[[@ref7][@ref8]\] Pregabalin is able to reduce the release of several excitatory neurotransmitters (e.g., glutamate, noradrenaline, serotonin, dopamine and substance P) through binding to the α-2-δ subunit of voltage-gated calcium channels.\[[@ref8][@ref9]\] Pain reduction can also be achieved by interacting with neurons in the spino-bulbo-spinal loop in the superficial dorsal horn and brainstem and blocking the development of hyperalgesia and central sensitisation.\[[@ref5][@ref9]\] Numerous studies have reported the efficacy of pregabalin in reducing acute post-operative pain.\[[@ref10][@ref11]\]

However, the use of pregabalin for post-operative pain of laparoscopic cholecystectomy has not been well established. Recently, several studies on the topic have been published, and the results have been conflicting.\[[@ref10][@ref12][@ref13][@ref14]\] Considering these inconsistent effects, we, therefore, conducted a systematic review and meta-analysis of randomised controlled trials (RCTs) to evaluate the influence of pregabalin on post-operative pain of laparoscopic cholecystectomy.

MATERIALS AND METHODS {#sec1-2}
=====================

This systematic review and meta-analysis are conducted according to the guidance of the Preferred Reporting Items for Systematic Reviews and Meta-analysis statement\[[@ref15]\] and the Cochrane Handbook for Systematic Reviews of Interventions.\[[@ref16]\] No ethical approval and patient consent are required because all analyses are based on previously published studies.

Literature search and selection criteria {#sec2-1}
----------------------------------------

PubMed, Embase, Web of Science, EBSCO and the Cochrane library are systematically searched from inception to June 2018, with the following keywords: laparoscopic cholecystectomy and pregabalin. To include additional eligible studies, the reference lists of retrieved studies, relevant conference abstracts and reviews are also hand-searched, and the process above is performed repeatedly until no further article is identified.

Study eligibility criteria {#sec2-2}
--------------------------

Participants (P): Patients undergoing laparoscopic cholecystectomy.

Intervention (I): Intervention: pre-emptive pregabalin.

Control (Comparison) (C): Matched placebo.

Outcome (O). Primary outcomes: pain scores at 8--12 h and 20--24 h. Secondary outcomes: sedation score, intraoperative fentanyl requirement, post-operative analgesic requirement, operative duration, post-operative nausea and vomiting, as well as respiratory depression. The study design is RCT.

The exclusion criteria are as follows: impaired liver or kidney functions, chronic pain, a daily intake of analgesics or corticosteroid.

Data extraction and outcome measures {#sec2-3}
------------------------------------

The following information is extracted for the included RCTs: First author, publication year, sample size, body relevant conference abstracts and reviews weight, the American Society of Anesthesiology (ASA) and detailed methods of two groups. The author would be contacted to acquire the data when necessary.

Quality assessment in individual studies {#sec2-4}
----------------------------------------

The Jadad Scale is used to evaluate the methodological quality of each RCT included in this meta-analysis.\[[@ref17]\] This scale consists of three evaluation elements: randomisation (0--2 points), blinding (0--2 points) and dropouts and withdrawals (0--1 points). One point would be allocated to each element if they have been mentioned in the article, and another one point would be given if the methods of randomisation and/or blinding have been appropriately described. If the methods of randomisation and/or blinding are inappropriate, or dropouts and withdrawals have not been recorded, then one point is deducted. The score of the Jadad Scale varies from 0 to 5 points. An article with Jadad score ≤2 is considered to be of low quality. If the Jadad score ≥3, the study is thought to be of high quality.\[[@ref18]\]

Statistical analysis {#sec2-5}
--------------------

Standard mean differences (Std. MDs) with 95% confidence intervals (CIs) for continuous outcomes (pain scores at 8--12 h and 20--24 h, sedation score, intraoperative fentanyl requirement, post-operative analgesic requirement and operative duration) and risk ratios with 95% CIs for dichotomous outcomes (post-operative nausea and vomiting, as well as respiratory depression) are used to estimate the pooled effects. The random-effects model is used for all the meta-analysis. An *I*^2^ value \>50% indicates significant heterogeneity. Sensitivity analysis is performed to detect the influence of a single study on the overall estimate through omitting one study in turn or undergo subgroup analysis when necessary. Owing to the limited number (\<10) of included studies, publication bias is not assessed. *P* \< 0.05 in two-tailed tests is considered statistically significant. All statistical analyses are performed with Review Manager Version 5.3 (The Cochrane Collaboration, Software Update, Oxford, UK).

RESULTS {#sec1-3}
=======

Literature search, study characteristics and quality assessment {#sec2-6}
---------------------------------------------------------------

[Figure 1](#F1){ref-type="fig"} shows the diagram of meta-analysis search strategy and selection process. In all, 549 studies in the first search seem to be potentially relevant. One hundred and forty-two duplicates are removed. A total of 395 studies are excluded (irrelevant subjects) on the basis of initial screening of the titles and/or abstracts, and four studies are removed for not being RCTs. Ultimately, eight RCTs are included in the meta-analysis.\[[@ref10][@ref12][@ref13][@ref14][@ref19][@ref20][@ref21][@ref22]\]

![Flow diagram of study searching and selection process](JMAS-16-99-g001){#F1}

The baseline characteristics of eight eligible RCTs in the meta-analysis are summarised in [Table 1](#T1){ref-type="table"}. The eight studies are published between 2008 and 2016, and sample sizes range from 34 to 120 with a total of 528. There are a similar age, male, body weight and ASA status between pregabalin group and control group at baseline. The doses of pregabalin vary from 150 mg to 600 mg preoperatively or in combination with post-operative use.

###### 

Characteristics of included studies

  *n*   Author               Pregabalin group   Control group   Jada scores                                                                                                                                                                                               
  ----- -------------------- ------------------ --------------- ------------- ----------- ------- -------------------------------------------------------------------------------------------------------- ---- -------------- ---- ----------- ------- ----------------- ---
  1     Mishra 2016          30                 35.8±8.43       14            59.2±6.44   \-      2 capsules of 75 mg pregabalin 1 h before induction of anaesthesia                                       30   35.67±8.59     9    57±6.9      \-      Matched placebo   4
  2     Gurunathan 2016      16                 41.0±12.5       4             \-          \-      Pregabalin 150 mg approximately 1 h before surgery                                                       18   45.9±14.7      4    \-          \-      Matched placebo   3
  3     Bekawi 2014          30                 37.6±6.9        5             77.9±10     24/6    150 mg pregabalin capsules 2 h pre-operative, 12 h post-operative and twice daily for 2 days             30   37.6±7.9       3    73.5±7.4    25/5    Matched placebo   5
  4     Sarakatsianou 2013   20                 53 (18-72)      12            \-          7/13    300 mg the night before surgery and 300 mg 1 h preoperatively                                            20   53 (18-72)     12   \-          11/9    Matched placebo   3
  5     Balaban 2012         30                 52.7±11.8       8             51.4±15.7   \-      300 mg pregabalin orally 1 h before surgery                                                              30   51.4±15.7      6    74.9±13.7           Matched placebo   4
  6     Gupta 2011           60                 44.23±15.3      21            65.4±12.8   34/26   150 mg pregabalin orally 70-90 min before surgery                                                        60   48.46±16.4     22   63.6±11.2   36/24   Matched placebo   3
  7     Peng 2010            48                 43 (22-65)      20            \-          \-      75 mg pregabalin orally 1 h before surgery, then every 12 h after operation for a total of three doses   46   47 (21-65)     13   \-          \-      Matched placebo   4
  8     Agarwal 2008         30                 46.6 (25-76)    23            56.2±10.1   \-      150 mg pregabalin orally 1 h before surgery                                                              30   44.6 (22-69)   18   55.7±9.1    \-      Matched placebo   5

ASA: American Society of Anesthesiology

Among the eight RCTs, four studies report pain scores at 8--12 h and 20--24 h,\[[@ref10][@ref12][@ref20][@ref21]\] three studies report sedation score,\[[@ref12][@ref14][@ref21]\] three studies report intraoperative fentanyl requirement,\[[@ref20][@ref21][@ref22]\] four studies report post-operative analgesic requirement,\[[@ref12][@ref14][@ref20][@ref21]\] six studies report operative duration,\[[@ref10][@ref12][@ref14][@ref19][@ref21][@ref22]\] five studies report post-operative nausea and vomiting,\[[@ref10][@ref12][@ref14][@ref20][@ref21]\] as well as two studies report respiratory depression.\[[@ref12][@ref21]\] Jadad scores of the eight included studies vary from 3 to 5, and all eight studies are considered to be high-quality ones according to quality assessment.

Primary outcomes: pain scores at 8--12 h and 20--24 h {#sec2-7}
-----------------------------------------------------

These two outcome data are analysed with the random-effects model, and the pooled estimate of four included RCTs suggested that compared to control group for laparoscopic cholecystectomy, pre-emptive pregabalin shows no substantial influence on pain scores at 8--12 h (Std. MD = −0.71; 95% CI = −1.70--0.27), with significant heterogeneity among the studies (*I*^2^ = 93%, heterogeneity *P* \< 0.00001) \[[Figure 2](#F2){ref-type="fig"}\]. However, pregabalin intervention is associated with a significantly decreased pain scores at 20--24 h (Std. MD = −0.46; 95% CI = −0.82--−0.10), with significant heterogeneity among the studies (I^2^ = 61%, heterogeneity *P* = 0.08) \[[Figure 3](#F3){ref-type="fig"}\].

![Forest plot for the meta-analysis of pain scores at 8--12 h](JMAS-16-99-g002){#F2}

![Forest plot for the meta-analysis of pain scores at 20--24 h](JMAS-16-99-g003){#F3}

Sensitivity analysis {#sec2-8}
--------------------

Significant heterogeneity is observed for pain scores at 8--12 h and 20--24 h. As shown in [Figure 2](#F2){ref-type="fig"}, the study conducted by Agarwal *et al.* showed the results that are almost out of range of the others and probably contribute to the heterogeneity.\[[@ref21]\] After excluding this study, the results suggest that pre-emptive pregabalin cannot reduce pain scores at 8--12 h (Std. MD = −0.09; 95% CI = −0.36--0.18;), and there is no heterogeneity among the remaining RCTs (*I*^2^ = 0%, heterogeneity *P* = 0.65).

As shown in [Figure 4](#F4){ref-type="fig"}, we perform subgroup analysis of pain scores at 20--24 h between the pre-operative use and the pre- and post-operative combination use. No heterogeneity remains among the subgroup analysis (*I*^2^ = 0%). Both methods of use are effective to reduce pain scores at 20--24 h and the pre-operative use may have better ability to alleviate post-operative pain after laparoscopic cholecystectomy.

![Forest plot for the subgroup-analysis of pain scores at 20--24 h](JMAS-16-99-g004){#F4}

Secondary outcomes {#sec2-9}
------------------

Compared with control intervention for laparoscopic cholecystectomy, pregabalin shows improved sedation score \[Std. MD = 0.92; 95% CI = 0.55--1.29; [Figure 5](#F5){ref-type="fig"}\], but has no substantial impact on intraoperative fentanyl requirement \[Std. MD = 0.04; 95% CI = −0.30--0.39; [Figure 6](#F6){ref-type="fig"}\]. Post-operative analgesic requirement in pregabalin group is significantly less than that in control group \[Std. MD = −2.64; 95% CI = −3.94--−1.33; [Figure 7](#F7){ref-type="fig"}\]. In addition, in comparison with control intervention after laparoscopic cholecystectomy, pregabalin treatment shows no notable influence on operative duration \[Std. MD = 0.34; 95% CI = −0.10--0.77; [Figure 8](#F8){ref-type="fig"}\]. Post-operative nausea and vomiting \[Std. MD = 0.79; 95% CI = 0.59--1.11; [Figure 9](#F9){ref-type="fig"}\], as well as respiratory depression \[Std. MD = 0.71; 95% CI = 0.17--3.02; [Figure 10](#F10){ref-type="fig"}\] in pregabalin group seem to be lower than that in control group, but with no significant difference.

![Forest plot for the meta-analysis of sedation score](JMAS-16-99-g005){#F5}

![Forest plot for the meta-analysis of intraoperative fentanyl requirement (μg)](JMAS-16-99-g006){#F6}

![Forest plot for the meta-analysis of post-operative analgesic requirement](JMAS-16-99-g007){#F7}

![Forest plot for the meta-analysis of operative duration (min)](JMAS-16-99-g008){#F8}

![Forest plot for the meta-analysis of post-operative nausea and vomiting](JMAS-16-99-g009){#F9}

![Forest plot for the meta-analysis of respiratory depression](JMAS-16-99-g010){#F10}

DISCUSSION {#sec1-4}
==========

Pregabalin is known as a structural analogue of gamma-aminobutyric acid with antinociceptive and antihyperalgesic properties and is effective to alleviate peripheral neuropathic pain,\[[@ref23][@ref24][@ref25][@ref26][@ref27]\] prevent neuropathic component of the acute nociceptive pain of surgery, produce a more opioid-sparing effect and the amelioration of perioperative anxiety. The action mechanism of pregabalin is probably the same as gabapentin but with a superior pharmacokinetic profile.\[[@ref28]\] Several clinical trials have revealed the efficacy of pregabalin for treating symptoms of generalised anxiety disorder.\[[@ref29][@ref30]\]

A single pre-operative dose of pregabalin is found to significantly attenuate postoperatively static (at rest) and dynamic pain and opioid consumption.\[[@ref21]\] However, in a randomised placebo-controlled trial, a single pre-operative dose of 100 mg pregabalin is ineffective to reduce acute post-operative pain or to improve recovery after minor surgery involving only the uterus, possibly because a smaller dose (100 mg) is lower than the recommended starting dose of 150 mg.\[[@ref31]\] The timing of first rescue analgesic postoperatively in one included RCT is significantly more in pregabalin group (343.16 ± 9.69 min) compared to gabapentin (158 ± 13.10 min) and placebo (4.67 ± 14.79 min) groups. In addition, pregabalin (64.67 ± 16.69 mg) group has consumed significantly less tramadol as compared to the gabapentin (116.13 ± 14.08 mg) and placebo (169.87 ± 20.32 mg) group.\[[@ref12]\]

Our meta-analysis suggests that pregabalin treatment is associated with significantly reduced pain scores at 20--24 h and post-operative analgesic requirement, but showed no substantial influence on pain scores at 8--12 h, intraoperative fentanyl requirement and operative duration after laparoscopic cholecystectomy. Pre-operative pregabalin administration (oral 75--300 mg) is reported to increase perioperative sedation in a dose-related fashion, and pregabalin 300 mg may lead to more severity of sedation than that of pregabalin 150 mg.\[[@ref32]\] When comparing the analgesic efficacy of gabapentin and pregabalin in surgery under spinal anaesthesia, total post-operative analgesic time is significantly more in pregabalin (14.17 h) as compared to gabapentin (8.98 h) group.\[[@ref33]\] Improved sedation score is observed after pregabalin use for laparoscopic cholecystectomy in our meta-analysis, and pregabalin reduces on average nausea, vomiting and respiratory depression, but there is no sufficient evidence to support this observation. Regarding the sensitivity analysis, different doses and the time of pregabalin use may account for the heterogeneity.

Several limitations should be taken into account. First, our analysis was based on only eight RCTs and seven of them have a relatively small sample size (*n* \< 100). Overestimation of the treatment effect is more likely in smaller trials compared with larger samples. Next, different doses and methods of pregabalin treatment in each included RCTs may result in the heterogeneity. Finally, some unpublished and missing data might lead to bias to the pooled effect.

CONCLUSIONS {#sec1-5}
===========

Pregabalin treatment is effective to alleviate post-operative pain after laparoscopic cholecystectomy and is recommended to be administered in clinical work.
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